Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: A discouraging pilot study
Corresponding Author
Patrizia Dall'Igna
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Padua, Italy
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Via Giustiniani 3, 35128 Padua, ItalySearch for more papers by this authorGiovanni Cecchetto
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Padua, Italy
Search for more papers by this authorCarlo Dominici
Pediatric Hematology-Oncology Department, University “La Sapienza,” Rome, Italy
Search for more papers by this authorAlberto Donfrancesco
Pediatric Oncology Department, Ospedale Bambino Gesù, Rome, Italy
Search for more papers by this authorModesto Carli
Department of Pediatrics, Division of Hematology-Oncology, University of Padua, Padua, Italy
Search for more papers by this authorPaolo Indolfi
Department of Pediatrics, Division of Hematology-Oncology, II University of Naples, Naples, Italy
Search for more papers by this authorMaurizio Guglielmi
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Padua, Italy
Search for more papers by this authorGiorgio Perilongo
Department of Pediatrics, Division of Hematology-Oncology, University of Padua, Padua, Italy
Search for more papers by this authorCorresponding Author
Patrizia Dall'Igna
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Padua, Italy
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Via Giustiniani 3, 35128 Padua, ItalySearch for more papers by this authorGiovanni Cecchetto
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Padua, Italy
Search for more papers by this authorCarlo Dominici
Pediatric Hematology-Oncology Department, University “La Sapienza,” Rome, Italy
Search for more papers by this authorAlberto Donfrancesco
Pediatric Oncology Department, Ospedale Bambino Gesù, Rome, Italy
Search for more papers by this authorModesto Carli
Department of Pediatrics, Division of Hematology-Oncology, University of Padua, Padua, Italy
Search for more papers by this authorPaolo Indolfi
Department of Pediatrics, Division of Hematology-Oncology, II University of Naples, Naples, Italy
Search for more papers by this authorMaurizio Guglielmi
Department of Pediatrics, Division of Pediatric Surgery, University of Padua, Padua, Italy
Search for more papers by this authorGiorgio Perilongo
Department of Pediatrics, Division of Hematology-Oncology, University of Padua, Padua, Italy
Search for more papers by this author
REFERENCES
- 1Perilongo G, Shafford EA. Liver tumours. Pediatric update. Eur J Cancer 1999; 35: 953–959.
- 2Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522–1534.
- 3Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1959; 53: 457–481.
- 4Greenwood M. The natural duration of cancer. London: Department of Public Health and Medical Subjects;1956. 33 HMSO.
- 5Ortega JA, Douglass E, Feusner J, et al. A randomized trial of cisplatin/vincristine/5fluorouracil vs cisplatin/doxorubicin iv continuous infusion for the treatment of hepatoblastoma. Results from the Pediatric Intergroup Study (CCG-8881/POG-8945). ASCO Abstracts. J Clin Oncol 1994; 13: 416.
- 6Von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study committee of the Cooperative Paediatric Liver Tumor Study HB 89 of the German Society of Paediatric Oncology and Hematology. Eur J Cancer 1997; 33: 1243–1249.
- 7Plaschkes J, Perilongo G, Shafford E, et al. Pre-operative chemotherapy-cisplatin (PLA) and doxorubicin (DO) PLADO for the treatment of hepatoblastoma and hepatocellular carcinoma-results after 2 years' follow-up. Proceedings of the XXVIII SIOP Meeting, Vienna-Austria, October 1–5, 1996. Med Pediatr Onc 1996; 27: 256.
- 8Locking J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 341.
10.1023/A:1017142015279 Google Scholar
- 9Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409–422.
- 10Bin P, Boddy AV, English MW, et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res 1994; 14: 2279–2283.
- 11Fuchs J, Wenderoth M, von Schweinitz D, et al. Comparative activity of cisplatin, doxorubicin, carboplatin and etoposide in heterotransplanted hepatoblastoma. Cancer 1998; 83: 2400–2407.
10.1002/(SICI)1097-0142(19981201)83:11<2400::AID-CNCR21>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 12Seshimo K, Hamasaki K, Gohda E, et al. Effects of cisplatin, carboplatin, etoposide and human hapatocyte growth factor on the colony formation of four human liver cancer cell lines. Gan To Kagaku Ryoho 1993; 20: 1967–1972.
